In fact, the patients of the previous study were enrolled into a prospective, randomized, multicenter clinical trial if they had rapidly proliferating breast cancer [45], while our cohort was heterogeneous and 48% of the patients had a low Ki67 index. This evidence concerns the gene MKI67 and breast cancer.